Aton（3HB）株式概要アトンはフランスのバイオサイエンス企業である。 詳細3HB ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6報酬当社が推定した公正価値より99.5%で取引されている リスク分析過去5年間で収益は年間20.1%減少しました。 German市場と比較して、過去 3 か月間の株価の変動が非常に大きい収益が 100 万ドル未満 ( €657K )意味のある時価総額がありません ( €12M )+1 さらなるリスクすべてのリスクチェックを見る3HB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.009221.4% 割高 内在価値ディスカウントEst. Revenue$PastFuture-16m657k2016201920222025202620282031Revenue €656.9kEarnings €119.4kAdvancedSet Fair ValueView all narrativesAton 競合他社Genetic AnalysisSymbol: DB:8V8Market cap: €42.7m2investSymbol: XTRA:2INVMarket cap: €62.9mDarwinSymbol: MUN:7V0Market cap: €74.4mHeidelberg PharmaSymbol: XTRA:HPHAMarket cap: €130.5m価格と性能株価の高値、安値、推移の概要Aton過去の株価現在の株価€0.00952週高値€0.02652週安値€0.0002ベータ0.611ヶ月の変化1,025.00%3ヶ月変化800.00%1年変化181.25%3年間の変化-81.44%5年間の変化-96.21%IPOからの変化-91.05%最新ニュースNew Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (162% average daily change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (€657k revenue, or US$763k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€12.4m market cap, or US$14.4m).New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (€614k revenue, or US$714k). Market cap is less than US$10m (€6.04m market cap, or US$7.01m). Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).お知らせ • May 21Aton, Annual General Meeting, Jun 30, 2025Aton, Annual General Meeting, Jun 30, 2025. Location: 850 boulevard sebastien brant, illkirch graffenstaden FranceNew Risk • Nov 14New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.42m (US$9.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (162% increase in shares outstanding). Market cap is less than US$10m (€9.42m market cap, or US$9.91m).New Risk • Jul 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 163% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (61% average daily change). Shareholders have been substantially diluted in the past year (163% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€9.49m market cap, or US$10.3m).New Risk • May 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (47% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (€4.00m market cap, or US$4.35m).最新情報をもっと見るRecent updatesNew Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (162% average daily change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (€657k revenue, or US$763k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€12.4m market cap, or US$14.4m).New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (€614k revenue, or US$714k). Market cap is less than US$10m (€6.04m market cap, or US$7.01m). Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).お知らせ • May 21Aton, Annual General Meeting, Jun 30, 2025Aton, Annual General Meeting, Jun 30, 2025. Location: 850 boulevard sebastien brant, illkirch graffenstaden FranceNew Risk • Nov 14New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.42m (US$9.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (162% increase in shares outstanding). Market cap is less than US$10m (€9.42m market cap, or US$9.91m).New Risk • Jul 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 163% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (61% average daily change). Shareholders have been substantially diluted in the past year (163% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€9.49m market cap, or US$10.3m).New Risk • May 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (47% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (€4.00m market cap, or US$4.35m).New Risk • Nov 07New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.44m (US$9.02m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€8.44m market cap, or US$9.02m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).New Risk • Oct 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€13.3m market cap, or US$14.0m).New Risk • Jul 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (€15.9m market cap, or US$17.7m).お知らせ • May 07Hybrigenics Société Anonyme announced that it has received fundingHybrigenics Société Anonyme (ENXTPA:ALHYG) announced that it has received a round of funding on May 6, 2021. The company has issued common stock in the transaction.Is New 90 Day High Low • Feb 25New 90-day high: €0.30The company is up 47% from its price of €0.20 on 27 November 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.Is New 90 Day High Low • Feb 10New 90-day high: €0.23The company is up 31% from its price of €0.18 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.Is New 90 Day High Low • Jan 20New 90-day high: €0.22The company is up 19% from its price of €0.19 on 22 October 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.Is New 90 Day High Low • Nov 25New 90-day high: €0.21The company is up 18% from its price of €0.18 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period.株主還元3HBDE BiotechsDE 市場7D-22.4%0.9%3.2%1Y181.3%-12.2%2.5%株主還元を見る業界別リターン: 3HB過去 1 年間で-12.2 % の収益を上げたGerman Biotechs業界を上回りました。リターン対市場: 3HB過去 1 年間で2.5 % の収益を上げたGerman市場を上回りました。価格変動Is 3HB's price volatile compared to industry and market?3HB volatility3HB Average Weekly Movement354.1%Biotechs Industry Average Movement8.7%Market Average Movement6.1%10% most volatile stocks in DE Market13.6%10% least volatile stocks in DE Market2.7%安定した株価: 3HBの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 3HBの 週次ボラティリティ は、過去 1 年間で312%から354%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト19989Ayikoele Atayiwww.aton-group.comフランスでバイオサイエンス事業を展開。医薬品開発の前臨床および臨床サービス、モノクローナル抗体の製造、実験器具の製造、医療機器の設計および製造、ならびにヒト組織の提供に従事している。同社は1998年に設立され、フランスのストラスブールに本社を置いている。もっと見るAton 基礎のまとめAton の収益と売上を時価総額と比較するとどうか。3HB 基礎統計学時価総額€11.76m収益（TTM）-€115.68k売上高(TTM)€656.93k17.9xP/Sレシオ-101.7xPER（株価収益率3HB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計3HB 損益計算書（TTM）収益€656.93k売上原価€247.90k売上総利益€409.03kその他の費用€524.71k収益-€115.68k直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.00014グロス・マージン62.26%純利益率-17.61%有利子負債／自己資本比率302.8%3HB の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 12:27終値2026/05/22 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aton 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (162% average daily change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (€657k revenue, or US$763k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€12.4m market cap, or US$14.4m).
New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (€614k revenue, or US$714k). Market cap is less than US$10m (€6.04m market cap, or US$7.01m). Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).
お知らせ • May 21Aton, Annual General Meeting, Jun 30, 2025Aton, Annual General Meeting, Jun 30, 2025. Location: 850 boulevard sebastien brant, illkirch graffenstaden France
New Risk • Nov 14New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.42m (US$9.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (162% increase in shares outstanding). Market cap is less than US$10m (€9.42m market cap, or US$9.91m).
New Risk • Jul 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 163% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (61% average daily change). Shareholders have been substantially diluted in the past year (163% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€9.49m market cap, or US$10.3m).
New Risk • May 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (47% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (€4.00m market cap, or US$4.35m).
New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (162% average daily change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (€657k revenue, or US$763k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€12.4m market cap, or US$14.4m).
New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (€614k revenue, or US$714k). Market cap is less than US$10m (€6.04m market cap, or US$7.01m). Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).
お知らせ • May 21Aton, Annual General Meeting, Jun 30, 2025Aton, Annual General Meeting, Jun 30, 2025. Location: 850 boulevard sebastien brant, illkirch graffenstaden France
New Risk • Nov 14New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.42m (US$9.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (162% increase in shares outstanding). Market cap is less than US$10m (€9.42m market cap, or US$9.91m).
New Risk • Jul 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 163% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (61% average daily change). Shareholders have been substantially diluted in the past year (163% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€9.49m market cap, or US$10.3m).
New Risk • May 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (47% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (€4.00m market cap, or US$4.35m).
New Risk • Nov 07New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.44m (US$9.02m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€8.44m market cap, or US$9.02m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).
New Risk • Oct 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€13.3m market cap, or US$14.0m).
New Risk • Jul 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (€15.9m market cap, or US$17.7m).
お知らせ • May 07Hybrigenics Société Anonyme announced that it has received fundingHybrigenics Société Anonyme (ENXTPA:ALHYG) announced that it has received a round of funding on May 6, 2021. The company has issued common stock in the transaction.
Is New 90 Day High Low • Feb 25New 90-day high: €0.30The company is up 47% from its price of €0.20 on 27 November 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.
Is New 90 Day High Low • Feb 10New 90-day high: €0.23The company is up 31% from its price of €0.18 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.
Is New 90 Day High Low • Jan 20New 90-day high: €0.22The company is up 19% from its price of €0.19 on 22 October 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Nov 25New 90-day high: €0.21The company is up 18% from its price of €0.18 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period.
